Lyell Immunopharma shares jump 13.54% after-hours after acquiring global rights to next-gen CAR T-cell therapy for colorectal cancer.

Lyell Immunopharma surged 13.54% in after-hours trading following multiple positive developments, including the acquisition of global rights to a next-generation CAR T-cell therapy candidate for metastatic colorectal cancer and the initiation of a Phase 3 head-to-head clinical trial for aggressive large B-cell lymphoma. Recent announcements also highlighted durable complete response rates from its Phase 1/2 trial of ronde-cel, reinforcing therapeutic potential. These advancements, coupled with strategic partnerships and clinical progress, underscored investor confidence in the company’s pipeline, driving the sharp post-market rally.